POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (5.13.2021, 12:396pm CEST, WHO):   U.S. 36,412    India 362,727    Brazil 72,715    France 18,323    Turkey 14,497    Russia 8,115    The United Kingdom 2,474    Italy 6,943    Spain 2,768    Germany 14,909    Argentina 25,976    Columbia 16,425    Poland 4,159    Iran 16,409    Mexico 1,897    Ukraine 4,538    Peru 4,869    Indonesia 4,608    Czechia 1,686    South Africa 2,759    The Netherlands 5,586    Canada 5,386    Chile 3,902    Iraq 4,666    Philippines 4,812    Romania 1,156    Sweden 2,463    Pakistan 2,881    Bangladesh 1,140    Serbia 1,125    Japan 6,927    United Arab Emirates 1,508    Malaysia 4,765    Saudi Arabia 1,020    Nepal 9,238    Greece 3,172    Croatia 1,471    Georgia 1,409    Tunisia 1,105    Bolivia 2,369    Paraguay 2,377    Costa Rica 2,236    Lithuania 1,266    Egypt 1,187    Guatemala 1,416    Uruguay 2,977    Honduras 1,130    Bahrain 1,539    Sri Lanka 1,429    Cuba 1,207    Thailand 14,887    Maldives 1,572    China 32    Singapore 16    New Zealand 1    Australia 8    South Korea 715   

Update: AstraZeneca U.S. data vaccine has 76 percent overall efficacy

Christian Fernsby |
AstraZeneca's said its COVID-19 vaccine has been 76 percent effective in a new analysis of its U.S. trial only a tad lower than the level in an earlier report.

Article continues below




Interim data published on Monday had put the vaccine's efficacy rate at 79 percent but had not included more recent infections, leading to a highly unusual public rebuke from US health officials.

AstraZeneca also reiterated that the shot, developed with Oxford University, was 100 percent effective against severe or critical forms of the disease. There have been eight severe cases – all among trial participants who received the placebo.

The latest data was based on 190 infections among more than 32,400 participants in the United States, Chile and Peru. The earlier interim data was based on 141 infections through February 17.

It also said the vaccine showed 85 percent efficacy in adults 65 years and older, higher than the 80 percent rate reported on Monday.


What to read next

Romania and Thailand suspends AstraZeneca vaccine, Germany and France not worried
New vaccine to provide 2-year protection
Moderna begins testing next-generation coronavirus vaccine